| Drug Class | Anti-platelet agent |
|---|---|
| Mechanism | Irreversibly to the platelet P2Y12 receptor, inhibiting ADP-mediated platelet activation and aggregation |
| Typical Dose | 75mg OD or 300mg loading dose |
| Indications | * Secondary prevention of atherosclerotic events * Prior to PCI to prevent atherothrombotic events |
| Contra-indications | * Active bleeding * Breast feeding |
| Side-effects | * Dyspepsia * Abdo pain * Diarrhoea * Bleeding disorders |
| Interactions | NSAIDs - increased risk of haemorrhage |
| Elimination | 50% urine 50% faeces |
| Additional Notes |